NCT03531294View on ClinicalTrials.gov

Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 23, 2018

Primary Completion Date

April 9, 2021

Study Completion Date

April 9, 2021

Conditions
Diabetic Retinopathy
Interventions
DRUG

Aflibercept Injection

intravitreal 2mg aflibercept injection

Trial Locations (2)

77030

Retina Consultants of Houston/The Medical Center, Houston

77384

Retina Consultants of Houston, The Woodlands

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

collaborator

The Cleveland Clinic

OTHER

lead

Greater Houston Retina Research

OTHER

NCT03531294 - Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement | Biotech Hunter | Biotech Hunter